Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By |2020-07-09T16:00:18-04:00September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By |2018-07-06T13:59:34-04:00January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Our Decision to Enter Hospice

I’ve been thinking a lot about writing this article. The last thing I want to do is cause worry or pain to anyone reading this. Then I thought of all the people who could possibly benefit in the future from knowing ahead of time what we didn’t know at the time we needed to know it.

By |2018-07-06T13:30:18-04:00June 11th, 2013|Coping with GIST, News, Sutent|

Sutent Treatment Use Trial Results

Patients with GIST who received sunitinib using a flexible dose approach to manage adverse events remained on treatment longer than those who received the strict dose/schedule and exhibited better clinical outcomes (longer time to tumor progression and longer overall survival).

By |2019-09-20T13:24:08-04:00January 9th, 2013|Coping with GIST, News, Side Effects, Sutent|

LRG Survey Seeks to Understand Differences in Sutent Dosage Schedules

The Life Raft Group surveyed patients and physicians about dosing options for the drug Sutent (sunitinib) to follow up on a 2011 study that showed that patients on a continuous dose exhibited better clinical outcomes than those on the standard four-week on, two-week off dosing regimen.

By |2019-09-20T13:24:43-04:00January 9th, 2013|News, Sutent|

Sutent Cardiotoxicity – Better Monitoring for Sutent-Related Heart Problems May Be Warranted

Reviews of patients treated at three major cancer centers suggest that Sutent-related heart problems may be more common than initially reported. Reports of heart failure ranged from eight percent in 75 GIST patients treated [...]

By |2019-04-08T11:49:05-04:00March 1st, 2009|Sutent|
Go to Top